USA flag logo/image

An Official Website of the United States Government

SBIR Phase I: Metabolomics of Human Embryonic Stem Cells to Predict…

Award Information

National Science Foundation
Award ID:
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
Solicitation Year:
Solicitation Topic Code:
Solicitation Number:
Small Business Information
504 S. Rosa Road MADISON, WI 53719-1256
View profile »
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No
Phase 1
Fiscal Year: 2009
Title: SBIR Phase I: Metabolomics of Human Embryonic Stem Cells to Predict Teratogenicity: An Alternative Developmental Toxicity Model
Agency: NSF
Contract: 0945105
Award Amount: $149,255.00


This Small Business Innovation Research (SBIR) Phase I project proposes to develop a highly predictive model for assessing the potential of compounds to cause birth defects in the developing human embryo using human embryonic stem (hES) cells as the test substrate. The project proposes to use hES cells and metabolomics to understand the impact of drugs and other chemicals on the development of the human embryo. These cells have the ability to differentiate into any cell in the body and as such, offer the opportunity to study defects in development in a way never available prior to the isolation of hES cells from an embryo. The broader impacts of this research are to increase the safety of compounds and to prevent birth defects resulting from exposure to drugs or other chemicals during pregnancy by more accurately predicting the potential for compounds to cause birth defects. Compound exposure is responsible for 4-5% of all birth defects, yet this is the most preventable type of birth defect. Currently, animal models are used to predict birth defects, however these tests are costly, time-consuming, and are only 60% predictive of the effect on human development. These animal models are the same tests that have been used for more than fifty years to predict the effect of drugs like Thalidomide and Accutane which have caused numerous birth defects in humans. More accurate screens are needed to predict if exposure to specific environmental chemicals or drugs will be hazardous to development.

Principal Investigator:

Paul R. West

Business Contact:

Paul R. West
Small Business Information at Submission:

Stemina Biomarker Discovery, inc.
504 S. Rosa Rd. Suite 150 Madison, WI 53719

EIN/Tax ID: 208294201
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No